BRISTOL, Tenn., July 20 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) reported today that the U.S. District Court in New Jersey
lifted its 1993 consent decree that pertained to King's sterile manufacturing
facility located in Rochester, Michigan. The Court vacated the consent decree
based on the Rochester facility's continued compliance with U.S. Food and Drug
Administration ("FDA") good manufacturing practices.
Brian A. Markison, President and Chief Executive Officer of King, stated,
"This is yet another important milestone for King. We are extremely pleased
with our manufacturing, quality assurance/quality control and regulatory
compliance teams, who have worked diligently to ensure that all of our
manufacturing facilities meet or exceed the good manufacturing practices
established by the FDA. We believe it was this continued diligence and
commitment that led the Court to lift the consent decree that affected our
Rochester facility."
King acquired the Rochester facility, which manufactures both drug and
biological pharmaceutical products, in February 1998. Prior to such
acquisition, the facility was one of six facilities then owned by Warner-
Lambert subject to a consent decree issued by the U.S. District Court in New
Jersey in August 1993.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs, +1-423-989-8125, or David E. Robinson, Senior
Director, Corporate Affairs, +1-423-989-7045, both of King
Pharmaceuticals, Inc.
|
